港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

英派藥業-B

36.220

-0.760-2.06%

成交量：43.72萬

成交額：1,567.24萬

市值：102.31億

市盈率：-25.14

高：36.600

開：36.600

低：35.060

收：36.980

52周最高：47.980

52周最低：28.200

股本：2.82億

香港流通股本：2.82億

量比：1.36

換手率：0.15%

股息：- -

股息率：- -

每股收益(LYR):-1.441

淨資產收益率：--

總資產收益率：-40.35%

市淨率：-9.26

市盈率(LYR):-25.14

市銷率: 232.01

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

英派藥業-B

交易所：

SEHK

成立時間：

2009

員工人數：

- -

公司地址：

New Bund Times Square,27th Floor,399 West Haiyang Road,Pudong New District,Shanghai,Shanghai Province,China

官網：

http://www.impacttherapeutics.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

南京英派藥業股份有限公司是一家主要從事生物技術研發和商業化的中國公司。該公司處於商業化階段。該公司致力於在全球範圍內推進基於合成致死（SL）機制的精準抗癌療法。該公司自主研發的核心產品塞納帕利已在中國獲批上市，作為卵巢癌（OC）一線維持療法。該公司正在研發的產品管線包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。

董事

名稱

職位

徐聰

董事會主席，非執行董事，提名委員會委員

蔡遂雄

執行董事

田野

執行董事

馬寧

執行董事，提名委員會委員

Qiang XU

非執行董事，薪酬委員會委員

劉濤

非執行董事，審計委員會委員

郭明

獨立非執行董事，薪酬委員會主席，提名委員會委員，審計委員會委員

蕭志雄

獨立非執行董事，薪酬委員會委員，提名委員會委員，審計委員會主席

邵黎明

獨立非執行董事，提名委員會主席

股東

名稱

職位

蔡遂雄

首席執行官

田野

常務副總裁，首席科學官

馬寧

常務副總裁

鄧慧君

財務總監

韓一凡

董事會秘書，聯席公司秘書，投資者關係副總監

葉翠媚

聯席公司秘書

許燕華

首席醫學官

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/07630/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派藥業-B","latestPrice":36.22,"timestamp":1782461289880,"preClose":36.98,"halted":0,"volume":437200,"delay":0,"changeRate":-0.020551649540291997,"floatShares":282461530,"shares":282461530,"eps":-1.440772,"marketStatus":"休市中","change":-0.76,"latestTime":"06-26 16:08:09","open":36.6,"high":36.6,"low":35.06,"amount":15672393,"amplitude":0.041644,"askPrice":36.22,"askSize":7400,"bidPrice":35.66,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.16,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":36.98,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":1.3625031169393553,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.440772,"volumeRatio":1.3625031169393553,"shares":282461530,"dividePrice":0,"high":36.6,"amplitude":0.041644,"preClose":36.98,"low":35.06,"week52Low":28.2,"pbRate":"-9.26","psRate":"232.01","week52High":47.98,"institutionHeld":0,"latestPrice":36.22,"committee":-0.947368,"eps":-1.440772,"divideRate":0,"volume":437200,"delay":0,"ttmEps":-1.16,"open":36.6,"prevYearClose":20.1,"prevWeekClose":37,"prevMonthClose":39.9,"prevQuarterClose":20.1,"fiveDayClose":37,"twentyDayClose":37.18,"sixtyDayClose":20.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-06-26","current":-31.224138,"percent":0.870968,"low":-34.323153,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"high":-16.800385,"avg":-30.174045,"sd":2.897097,"marketCap":10002701008},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008}],"updateTime":1782520399335},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":129927258,"yearFounded":2009,"address":"New Bund Times Square,27th Floor,399 West Haiyang Road,Pudong New District,Shanghai,Shanghai Province,China","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0403},{"period":"3month","weight":0.802},{"period":"ytd","weight":0.802}],"compareEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.1049},{"period":"3month","weight":-0.0914},{"period":"6month","weight":-0.1219},{"period":"1year","weight":-0.068},{"period":"ytd","weight":-0.1154}],"compareStock":{"symbol":"HSI","name":"恆生指數"},"description":"南京英派藥業股份有限公司是一家主要從事生物技術研發和商業化的中國公司。該公司處於商業化階段。該公司致力於在全球範圍內推進基於合成致死（SL）機制的精準抗癌療法。該公司自主研發的核心產品塞納帕利已在中國獲批上市，作為卵巢癌（OC）一線維持療法。該公司正在研發的產品管線包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。","exchange":"SEHK","name":"英派藥業-B","nameEN":"IMPACT THERAP-B"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":{"directors":[{"name":"徐聰","position":"董事會主席，非執行董事，提名委員會委員"},{"name":"蔡遂雄","position":"執行董事"},{"name":"田野","position":"執行董事"},{"name":"馬寧","position":"執行董事，提名委員會委員"},{"name":"Qiang XU","position":"非執行董事，薪酬委員會委員"},{"name":"劉濤","position":"非執行董事，審計委員會委員"},{"name":"郭明","position":"獨立非執行董事，薪酬委員會主席，提名委員會委員，審計委員會委員"},{"name":"蕭志雄","position":"獨立非執行董事，薪酬委員會委員，提名委員會委員，審計委員會主席"},{"name":"邵黎明","position":"獨立非執行董事，提名委員會主席"}],"executives":[{"name":"蔡遂雄","position":"首席執行官"},{"name":"田野","position":"常務副總裁，首席科學官"},{"name":"馬寧","position":"常務副總裁"},{"name":"鄧慧君","position":"財務總監"},{"name":"韓一凡","position":"董事會秘書，聯席公司秘書，投資者關係副總監"},{"name":"葉翠媚","position":"聯席公司秘書"},{"name":"許燕華","position":"首席醫學官"}]}}}